Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
Baxter
Fish and Richardson
Deloitte
Cerilliant
Chinese Patent Office
US Army
Healthtrust
UBS

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,115,587

« Back to Dashboard

Which drugs does patent 7,115,587 protect, and when does it expire?

Patent 7,115,587 protects ABILIFY and is included in one NDA.

Protection for ABILIFY has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-eight patent family members in thirty-one countries.
Summary for Patent: 7,115,587
Title:Aripiprazole complex formulation and method
Abstract:An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a .beta.-cyclodextrin, preferably, sulfobutyl ether .beta.-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
Inventor(s): Nerurkar; Manoj (Monmouth Junction, NJ), Naringrekar; Vijay (Paramus, NJ)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:10/642,366
Patent Claim Types:
see list of patent claims
Formulation; Use;

Drugs Protected by US Patent 7,115,587

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Otsuka ABILIFY aripiprazole INJECTABLE;INTRAMUSCULAR 021866-001 Sep 20, 2006 DISCN No No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,115,587

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,550,445 Aripiprazole complex formulation and method ➤ Subscribe
8,999,952 Aripiprazole complex formulation and method ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,115,587

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Brazil 0313602 ➤ Subscribe
Canada 2495864 ➤ Subscribe
China 1674882 ➤ Subscribe
China 100335047 ➤ Subscribe
Cyprus 1110331 ➤ Subscribe
Germany 60327225 ➤ Subscribe
Spain 2322953 ➤ Subscribe
Georgia, Republic of P20063996 ➤ Subscribe
Croatia P20050149 ➤ Subscribe
Israel 166623 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Cerilliant
Harvard Business School
Cantor Fitzgerald
Teva
Express Scripts
Medtronic
Johnson and Johnson
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot